Quantum BioPharma Ltd.

Quantum BioPharma Ltd. has applied for a voluntary delisting of its Class B subordinate voting shares from the Canadian Securities Exchange, with the last trading day expected to be September 4, 2026, subject to CSE approval. The company, which trades on Nasdaq under the symbol QNTM, will maintain its listings on Nasdaq, the Frankfurt Stock Exchange, and Upstream, and will continue as a reporting issuer in Canada. Management cited the low trading volume on the CSE as no longer justifying the costs and regulatory burdens of a dual listing, and expects that consolidating trading on Nasdaq will benefit long-term liquidity. Shareholders holding shares through Canadian brokers need not take action, but should confirm their accounts can trade on Nasdaq. The delisting does not affect the company's other listings.

Quantum BioPharma has closed the settlement of CAD$123,487.43 in debt owed to arm’s length creditors and insiders through the issuance of Class B subordinate voting shares. The shares were issued at a deemed price of CAD$3.99 per Class B Share, representing the closing price on the Canadian Securities Exchange on the trading day immediately prior to the closing date. In full settlement of the debt, the company issued an aggregate of 30,948 Class B Shares to the creditors.